CELALETTİN EROĞLU, ESİN KİRAZ, OLGUN KONTAŞ, AHMET ÖZTÜRK
Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi - 2023;18(1):67-72
Objective: In this study, we aimed to determine the predictive and prognostic value of NQO1 in patients with stage III non-small cell lung cancers (NSCLC) treated with concomitant chemoradiotherapy. Materials and Methods: 64 patients with stage III NSCLC treated with concomitant cisplatin + docetaxel chemoradiotherapy were enrolled to the study. NQO1 immunohistochemical (IHC) staining was performed on the pathology preparations of the patients and compared in terms of the negative and positivity. Results: The median age was 63 (range, 35-83 years). Most of the patients (86%, n=55) were male. 27% (n=17) of the patients were stage IIIA, 56% (n=36) were stage IIIB, and 17% (n=11) were stage IIIC. The patients were histopathologically classified as 47% (n=30) adenocarcinoma, 47% (n=30) as epidermoid carcinoma, and 6% (n=4) as NSCLC, Not otherwise specified. Median follow-up was 20 months (range, 3-7 months). As a result of the IHC staining of NQO1, 7 (11%) of the 64 patients were negative, 11 (17%) of the 64 patients were (+) positive, 14 (22%) of the 64 patients were (++) positive and 32 (50%) of the 64 patients were (+++) positive. Median overall survival of patients according to NQO1; was found 21 months in (-)’s, 19 months in (+)’s, 16 months in (++)’s and 19 months in (+++)’s. Although the median overall survival in patients with positive NQO1 was numerically lower than in patients with negative NQO1, which was not statistically significant (p=0.801). Conclusion: NQO1 may be a prognostic factor in patients with stage III NSCLC treated with concomitant chemoradiotherapy, but further studies with a larger number of patients are needed.
